Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury

Liraglutide (Lir) is a glucagon-like peptide-1 receptor agonist that lowers blood sugar and reduces myocardial infarct size by improving endothelial cell function. However, its mechanism has not yet been clarified. Unfolded protein response (UPR) plays an important role in the pathogenesis of myocar...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chong, Liu, Yong, He, Jing, Mu, Rong, Di, Yanbo, Shen, Na, Liu, Xuan, Gao, Xiao, Wang, Jinhui, Chen, Tie, Fang, Tao, Li, Huanming, Tian, Fengshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664686/
https://www.ncbi.nlm.nih.gov/pubmed/31396081
http://dx.doi.org/10.3389/fphar.2019.00789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664686/
https://www.ncbi.nlm.nih.gov/pubmed/31396081
http://dx.doi.org/10.3389/fphar.2019.00789

Ejemplares similares